[1] Faiz AS, Khan I, Beckman MG, et al. Characteristics and risk factors of cancer associated venous thromboembolism[J].Thromb Res, 2015,136(3):535-541.
[2] Couzin-Frankel J.Breakthrough of the year 2013.Cancer immunotherapy[J].Science, 2013,342(6165):1432-1433.
[3] Dammacco F, Vacca A, Procaccio P, et al. Cancer-related coagulopathy (Trousseau's syndrome):review of the literature and experience of a single center of internal medicine[J].Clin Exp Med, 2013,13(2):85-97.
[4] Tas F,Ciftci R, Kilic L, et al. Clinical and prognostic significance of coagulation assays in melanoma[J].Melanoma Res,2012,22(5):368-395.
[5] Liu P, Zhu Y, Liu L. Elevated pretreatment plasma D-dimer levels and platelet counts predict poor prognosis in pancreatic adenocarcinoma[J].Oncol Targets Ther, 2015, 4(8):1335-1340.
[6] Yamamoto M, Yoshinaga K, Matsuyama A, et al. Plasma D-dimer level as a mortality predictor in patients with advanced or recurrent colorectal cancer[J]. Oncology, 2012,83(1):10-15.
[7] Inanc M, Er O, Karaca H, et al. D-dimer is a marker of response to chemotherapy in patients with metastatic colorectal cancer[J]. BUON, 2013,18(2):391-397.
[8] Lal I, Dittus K, Holmes CE. Platelets, coagulation and fibrinolysis in breast cancer progression[J]. Breast Cancer Res, 2013,15(4):207.
[9] Zhang X, Ran Y. Prognostic role of elevated platelet count in patients with lung cancer:a systematic review and meta-analysis[J]. Int J Clin Exp Med, 2015,8(4):5379-5387.
[10] Khalil J, Bensaid B, Elkacemi H,et al. Venous thromboembolism in cancer patients:an underestimated major health problem[J]. World J Surg Oncol, 2015,13:204.
[11] Afshar M, Hamilton P, Seligmann J, et al. Can D-Dimer Measurement Reduce the Frequency of Radiological Assessment in Patients Receiving Palliative Imatinib for Gastrointestinal Stromal Tumor (GIST)[J]. Cancer Invest, 2015,33(8):347-353.
[12] Rhode S, Paul MC, Martens E, et al. Simulation of haemodynamic flow in head and neck cancer chemotherapy[J].Biomed Eng Online, 2011,10:104.
[13] Bremm M, Huenecke S, Zimmermann O, et al. In-vitro influence of mycophenolate mofetil (MMF) and ciclosporin A (CsA) on cytokine induced killer (CIK) cell immunotherapy[J].J Transl Med, 2016,14:264.
[14] Yang L, Ren B, Li H, et al. Enhanced antitumor effects of DC-activated CIKs to chemotherapy treatment in a single cohort of advanced non-small-cell lung cancer patients[J]. Cancer Immunol Immunother, 2013,62(1):65-73.
[15] Wang S, Wang Z. Efficacy and safety of dendritic cells co-cultured with cytokine-induced killer cells immunotherapy for non-small-cell lung cancer[J]. Int Immunopharmacol, 2015,28(1):22-28.
[16] Ren J, Di L, Song G, et al. Selections of appropriate regimen of high-dose chemotherapy combined with adoptive cellular therapy with dendritic and cytokine-induced killer cells improved progression-free and overall survival in patients with metastatic breast cancer:reargument of such contentious therapeutic preferences[J]. Clin Transl Oncol, 2013,15(10):780-788.
[17] Zhan HL, Gao X, Pu XY, et al. A randomized controlled trial of postoperative tumor lysate-pulsed dendritic cells and cytokine-induced killer cells immunotherapy in patients with localized and locally advanced renal cell carcinoma[J]. Chin Med J, 2012,125(21):3771-3777.
[18] Lee JH, Lee JH, Lim YS, et al. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma[J].Gastroenterology, 2015,148(7):1383-1391. |